Home Neoplasma 2021 Neoplasma Vol.68, No.6, p.1301–1309, 2021

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.6, p.1301–1309, 2021

Title: Identification of plasma SAA2 as a candidate biomarker for the detection and surveillance of non-small cell lung cancer
Author: Fa-Fu Zhang, Bin Han, Run-Hao Xu, Qing-Qing Zhu, Qi-Qi Wu, Hui-Min Wei, Zhi-Lei Cui, Shu-Lin Zhang, Min-Jie Meng


This study aimed to measure the expression of SAA2 in plasma and to assess its diagnostic efficacy as a biomarker for non-small cell lung cancer (NSCLC). The gene expression of SAA2 in NSCLC was analyzed based on a database. Then, SAA2 expression was detected by immunohistochemistry in lung tissue and by enzyme-linked immunosorbent assay in 90 patients with NSCLC and 61 normal controls. Finally, the diagnostic performance was assessed in terms of accuracy, sensitivity, and specificity.

At the gene and protein levels, the SAA2 expression was significantly higher in the NSCLC group than in the control group (p < 0.01). It was higher in lung squamous carcinoma than in lung adenocarcinoma and in males than in females, and this trend was also observed in the lung squamous carcinoma group. Of note, the expression of SAA2 increased with increasing disease stage. Receiver operating characteristic (ROC) curve analysis revealed that the sensitivity of SAA2 was 83.61%, the specificity was 91.11%, and the area under the curve (AUC) was 0.9252. Its accuracy was 68.89%, which was higher than that of other conventional diagnostic biomarkers, and the combined application can effectively improve the diagnostic efficiency. Based on the results, SAA2 expression was positively correlated with the disease stage of NSCLC. Notably, SAA2 is more concerning in male patients with lung squamous carcinoma, and it can help in the screening and diagnosis of NSCLC. SAA2 may represent a novel diagnostic biomarker in NSCLC.

Keywords: non-small cell lung cancer; biomarkers; SAA2; diagnosis; immunohistochemistry
Published online: 14-Oct-2021
Year: 2021, Volume: 68, Issue: 6 Page From: 1301, Page To: 1309

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.